Last reviewed · How we verify

NCT05963945

Multi-Reader Retrospective Study Examining Carebot AI CXR 2.0.21-v2.01 Implementation in Everyday Radiology Clinical Practice

Completed Last updated 27 July 2023
What this trial tests

trial testing Carebot AI CXR in Pneumothorax in 956 participants. Completed in 21 March 2023.

Timeline
18 October 2022
Primary endpoint
17 November 2022
21 March 2023

Quick facts

Lead sponsorCarebot s.r.o.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment956
Start date18 October 2022
Primary completion17 November 2022
Estimated completion21 March 2023
Sites1 location across Czechia

Drugs / interventions tested

Conditions studied

Sponsor

Carebot s.r.o. — full company profile →

Who can join

18 and older, any sex, with Pneumothorax or Pulmonary Nodule, Solitary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective is to evaluate the performance parameters of the proposed DLAD (Carebot AI CXR) in comparison to individual radiologists.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Carebot AI CXR

Trials testing the same drug.

Other recruiting trials for Pneumothorax

Currently open trials in the same condition.

Other Carebot s.r.o. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05963945.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing